
## Joachim Sieper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7317380/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: Oneâ€Year Results of a Doubleâ€Blind, Placeboâ€Controlled Study and Openâ€Label Extension. Arthritis and Rheumatology, 2022, 74, 70-80.	5.6	38
2	What amount of structural damage defines sacroiliitis: a CT study. RMD Open, 2022, 8, e001939.	3.8	11
3	Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study. RMD Open, 2022, 8, e002174.	3.8	3
4	Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results. Rheumatology, 2022, 61, 3299-3308.	1.9	16
5	Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a <scp>Timeâ€Shifted</scp> Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: <scp>10â€Year</scp> Results From the German Spondyloarthritis Inception Cohort. Arthritis and Rheumatology. 2022. 74. 1515-1523.	5.6	11
6	MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2022, 81, 1243-1251.	0.9	22
7	Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2022, 81, 1252-1259.	0.9	7
8	Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Annals of the Rheumatic Diseases, 2022, 81, 1515-1523.	0.9	43
9	Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis. Rheumatology, 2021, 60, 269-276.	1.9	3
10	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open, 2021, 7, e001450.	3.8	64
11	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. Rheumatology, 2021, 60, 4778-4789.	1.9	44
12	Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with <i>a priori</i> different likelihoods of the diagnosis. Rheumatology, 2021, 60, 5098-5104.	1.9	7
13	Diagnostic delay in axial spondyloarthritis – a past or current problem?. Current Opinion in Rheumatology, 2021, 33, 307-312.	4.3	14
14	Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance. Arthritis Research and Therapy, 2021, 23, 106.	3.5	37
15	Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?. Current Opinion in Rheumatology, 2021, 33, 363-369.	4.3	3
16	Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis. RMD Open, 2021, 7, e001751.	3.8	3
17	What is the optimal target for a T2T approach in axial spondyloarthritis?. Annals of the Rheumatic Diseases, 2021, 80, annrheumdis-2021-220603.	0.9	4
18	Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2098770.	2.7	6

#	Article	IF	CITATIONS
19	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. RMD Open, 2021, 7, e001728.	3.8	5
20	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110579.	2.7	30
21	Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis. Joint Bone Spine, 2020, 87, 69-73.	1.6	11
22	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Annals of the Rheumatic Diseases, 2020, 79, 88-93.	0.9	63
23	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Annals of the Rheumatic Diseases, 2020, 79, 176-185.	0.9	76
24	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet, The, 2020, 395, 53-64.	13.7	138
25	Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa. Seminars in Arthritis and Rheumatism, 2020, 50, 1015-1021.	3.4	35
26	Treatment of Axial Spondyloarthritis: What Does the Future Hold?. Current Rheumatology Reports, 2020, 22, 47.	4.7	20
27	The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Research and Therapy, 2020, 22, 210.	3.5	16
28	Relation of α2-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis. International Journal of Molecular Sciences, 2020, 21, 9383.	4.1	1
29	The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097261.	2.7	17
30	Spondyloarthritides. , 2020, , 691-701.		1
31	Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. Rheumatology, 2020, 59, 3798-3806.	1.9	52
32	lgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. Clinical and Experimental Rheumatology, 2020, 38, 1127-1131.	0.8	5
33	Response to †Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier' by Alunno <i>et al</i> . Annals of the Rheumatic Diseases, 2019, 78, e55-e55.	0.9	0
34	Current Unmet Needs in Spondyloarthritis. Current Rheumatology Reports, 2019, 21, 43.	4.7	24
35	Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open, 2019, 5, e000917.	3.8	30
36	Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet, The, 2019, 394, 2108-2117.	13.7	223

#	Article	IF	CITATIONS
37	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2019, 78, 1550-1558.	0.9	171
38	The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nature Reviews Rheumatology, 2019, 15, 747-757.	8.0	78
39	Detection of Sacroiliitis by Short-tau Inversion Recovery and T2-weighted Turbo Spin Echo Sequences: Results from the SIMACT Study. Journal of Rheumatology, 2019, 46, 376-383.	2.0	16
40	Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 126.	3.5	2
41	Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology, 2019, 58, 1634-1638.	1.9	100
42	Treatment Guidelines for Axial Spondyloarthritis. , 2019, , 243-258.		0
43	Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. Rheumatology, 2019, 58, 1556-1564.	1.9	28
44	ls a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. Rheumatology, 2019, 58, 1649-1654.	1.9	23
45	SAT0347â€COMORBID CONDITIONS ARE ASSOCIATED WITH HIGHER DISEASE ACTIVITY AND WORSE FUNCTIONAL STATUS IN AXIAL SPONDYLOARTHRITIS: A POPULATION-BASED ANALYSIS OF INSURANCE CLAIMS LINKED TO PATIENT SURVEY DATA. , 2019, , .		0
46	THU0365â€THE IMPACT OF UVEITIS, PSORIASIS AND INFLAMMATORY BOWEL DISEASE ON MUSCULOSKELETA DISEASE ACTIVITY AND FUNCTION IN AXIAL SPONDYLOARTHRITIS: A POPULATION-BASED ANALYSIS OF INSURANCE CLAIMS LINKED TO PATIENT SURVEY DATA. , 2019, , .	٨L	1
47	THU0366â€MAGNETIC RESONANCE IMAGING IN COMPARISON WITH CONVENTIONAL RADIOGRAPHY FOR DETECTION OF STRUCTURAL CHANGES TYPICAL FOR SPA – DATA FROM THE ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) COHORT. , 2019, , .		0
48	SAT0305â€ASSOCIATION OF SKIN PSORIASIS WITH CLINICAL AND RADIOGRAPHIC CHARACTERISTICS IN AXIAI SPONDYLOARTHRITIS: RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT. , 2019, , .	-	0
49	Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open, 2019, 5, e001108.	3.8	77
50	Three Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 258-270.	5.6	237
51	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. RMD Open, 2019, 5, e000585.	3.8	41
52	Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Longâ€Term Anti–Tumor Necrosis Factor Treatment: Sixâ€Year Results of Continuous Treatment With Etanercept. Arthritis and Rheumatology, 2019, 71, 722-728.	5.6	21
53	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases, 2019, 78, 872-878.	0.9	36
54	Age- and Sex-dependent Frequency of Fat Metaplasia and Other Structural Changes of the Sacroiliac Joints in Patients without Axial Spondyloarthritis: A Retrospective, Cross-sectional MRI Study. Journal of Rheumatology, 2018, 45, 915-921.	2.0	33

#	Article	IF	CITATIONS
55	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. Journal of Rheumatology, 2018, 45, 506-512.	2.0	31
56	Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Rheumatology, 2018, 57, 703-711.	1.9	37
57	Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial. Arthritis Research and Therapy, 2018, 20, 61.	3.5	32
58	Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2. RMD Open, 2018, 4, e000566.	3.8	5
59	What low back pain is and why we need to pay attention. Lancet, The, 2018, 391, 2356-2367.	13.7	2,444
60	Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Annals of the Rheumatic Diseases, 2018, 77, 1017-1024.	0.9	44
61	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.9	484
62	What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?. Rheumatology, 2018, 57, 1145-1150.	1.9	25
63	Peripheral spondyloarthritis: Concept, diagnosis and treatment. Best Practice and Research in Clinical Rheumatology, 2018, 32, 357-368.	3.3	21
64	Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care. RMD Open, 2018, 4, e000825.	3.8	45
65	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. The, 2018, 392, 2441-2451.	13.7	251
66	An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus. Arthritis Research and Therapy, 2018, 20, 191.	3.5	11
67	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet, The, 2018, 392, 134-144.	13.7	81
68	Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort. Arthritis Research and Therapy, 2018, 20, 166.	3.5	16
69	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Annals of the Rheumatic Diseases, 2018, 77, 1295-1302.	0.9	275
70	Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study. Annals of the Rheumatic Diseases, 2018, 77, 1585-1589.	0.9	69
71	Axial spondyloarthritis. Lancet, The, 2017, 390, 73-84.	13.7	876
72	Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Annals of the Rheumatic Diseases, 2017, 76, 1070-1077.	0.9	213

#	Article	IF	CITATIONS
73	Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Annals of the Rheumatic Diseases, 2017, 76, 571-592.	0.9	137
74	Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. Annals of the Rheumatic Diseases, 2017, 76, 1502-1508.	0.9	136
75	Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC. RMD Open, 2017, 3, e000366.	3.8	24
76	Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis. Journal of Molecular Medicine, 2017, 95, 779-787.	3.9	19
77	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology, 2017, 56, 1498-1509.	1.9	78
78	Effects of Longâ€Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104â€Week Results From a Randomized, Placebo ontrolled Study. Arthritis Care and Research, 2017, 69, 1590-1598.	3.4	28
79	Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial. BMJ Open, 2017, 7,	1.9	17
80	Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time. Rheumatology, 2017, 56, 1162-1166.	1.9	29
81	Associations de patients atteints de spondylarthrite ankylosante–Âquelles différences entre membres et non-membresÂ?. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 231-237.	0.0	0
82	Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. Journal of Rheumatology, 2017, 44, 599-608.	2.0	39
83	Mechanism of New Bone Formation in Axial Spondyloarthritis. Current Rheumatology Reports, 2017, 19, 55.	4.7	58
84	Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial. Arthritis Research and Therapy, 2017, 19, 140.	3.5	40
85	Systematic review of clinical, humanistic, and economic outcome comparisons between radiographic and non-radiographic axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2017, 46, 746-753.	3.4	29
86	Disease activity in ankylosing spondylitis: the global therapeutic target. Annals of the Rheumatic Diseases, 2017, 77, annrheumdis-2017-212363.	0.9	6
87	Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Research and Therapy, 2017, 19, 240.	3.5	43
88	Genetic diagnostic profiling in axial spondyloarthritis: a real world study. Clinical and Experimental Rheumatology, 2017, 35, 229-233.	0.8	16
89	Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial. Arthritis and Rheumatology. 2016. 68. 1899-1903.	5.6	15
90	Course of Magnetic Resonance Imaging–Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Doubleâ€Blind, Placeboâ€Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods. Arthritis and Rheumatology, 2016, 68, 418-429.	5.6	42

#	Article	IF	CITATIONS
91	High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Annals of the Rheumatic Diseases, 2016, 75, 2114-2118.	0.9	103
92	New evidence on the management of spondyloarthritis. Nature Reviews Rheumatology, 2016, 12, 282-295.	8.0	104
93	Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. Rheumatology, 2016, 55, 1946-1953.	1.9	17
94	New treatment targets for axial spondyloarthritis: Table 1. Rheumatology, 2016, 55, ii38-ii42.	1.9	21
95	Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years. Journal of Rheumatology, 2016, 43, 2142-2148.	2.0	38
96	Granulation Tissue Eroding the Subchondral Bone Also Promotes New Bone Formation in Ankylosing Spondylitis. Arthritis and Rheumatology, 2016, 68, 2456-2465.	5.6	47
97	Ankylosing spondylitis self-help organisations –Âdo members differ from non-members?. Joint Bone Spine, 2016, 83, 295-300.	1.6	4
98	Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus. Journal of International Medical Research, 2016, 44, 216-230.	1.0	13
99	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2016, 75, 1958-1963.	0.9	383
100	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Annals of the Rheumatic Diseases, 2016, 75, 1034-1042.	0.9	53
101	Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?. Annals of the Rheumatic Diseases, 2016, 75, 1262-1263.	0.9	24
102	Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis—3-Year data of the ESTHER trial. Seminars in Arthritis and Rheumatism, 2016, 45, 404-410.	3.4	33
103	Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Annals of the Rheumatic Diseases, 2016, 75, 1328-1335.	0.9	81
104	Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2â€years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Annals of the Rheumatic Diseases, 2016, 75, 1438-1443.	0.9	163
105	Burden of illness associated with non-radiographic axial spondyloarthritis: a multiperspective European cross-sectional observational study. Clinical and Experimental Rheumatology, 2016, 34, 975-983.	0.8	10
106	Reply to the editorial: Can we currently and confidently assess the true burden of illness due to non-radiographic axial spondyloarthritis? by S. van der Linden and M.A. Khan. Clinical and Experimental Rheumatology, 2016, 34, 1121.	0.8	0
107	Axial spondyloarthritis. Nature Reviews Disease Primers, 2015, 1, 15013.	30.5	135
108	Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS. Arthritis Research and Therapy, 2015, 17, 170.	3.5	27

#	Article	IF	CITATIONS
109	Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort. Arthritis and Rheumatology, 2015, 67, 2369-2375.	5.6	28
110	Reply. Arthritis and Rheumatology, 2015, 67, 2793-2794.	5.6	3
111	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. New England Journal of Medicine, 2015, 373, 2534-2548.	27.0	803
112	In vivo pre-activation of monocytes in patients with axial spondyloarthritis. Arthritis Research and Therapy, 2015, 17, 179.	3.5	30
113	Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. Rheumatology, 2015, 54, 257-261.	1.9	18
114	The burden of non-radiographic axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2015, 44, 556-562.	3.4	112
115	Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology, 2015, 54, 1210-1219.	1.9	40
116	Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Annals of the Rheumatic Diseases, 2015, 74, 1483-1487.	0.9	99
117	Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis. Arthritis and Rheumatology, 2015, 67, 914-923.	5.6	67
118	Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression. Arthritis and Rheumatology, 2015, 67, 678-685.	5.6	67
119	Analysis of Bone Samples from Patients with Spondyloarthritides—Identifying Causes of New Bone Formation in Axial Spondyloarthritis. Journal of Rheumatology, 2015, 42, 561-563.	2.0	3
120	Classification and Diagnosis of Axial Spondyloarthritis — What Is the Clinically Relevant Difference?. Journal of Rheumatology, 2015, 42, 31-38.	2.0	37
121	Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Annals of the Rheumatic Diseases, 2015, 74, 1051-1057.	0.9	128
122	Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 1241-1248.	0.9	176
123	Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: †Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' by van Hoeven <i>et al</i> . Annals of the Rheumatic Diseases. 2015. 74. 1-1.	0.9	3
124	Management of ankylosing spondylitis/axial spondyloarthritis. , 2015, , 970-985.		1
125	I59. New Biologic Treatments for Ankylosing Spondylitis. Rheumatology, 2014, 53, i13-i13.	1.9	0
126	Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 1746-1748.	0.9	71

#	Article	IF	CITATIONS
127	Histomorphologic and Histomorphometric Characteristics of Zygapophyseal Joint Remodeling in Ankylosing Spondylitis. Arthritis and Rheumatology, 2014, 66, 1745-1754.	5.6	54
128	Similarities and differences between nonradiographic and radiographic axial spondyloarthritis. Current Opinion in Rheumatology, 2014, 26, 377-383.	4.3	58
129	Cood correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. Arthritis Research and Therapy, 2014, 16, R35.	3.5	32
130	Clinician's Manual on Axial Spondyloarthritis. , 2014, , .		3
131	Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2014, 66, 667-673.	5.6	65
132	Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 2137-2143.	0.9	62
133	Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 710-715.	0.9	238
134	Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Annals of the Rheumatic Diseases, 2014, 73, 95-100.	0.9	181
135	Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2014, 66, 2091-2102.	5.6	185
136	Erosions and Fatty Lesions of Sacroiliac Joints in Patients with Axial Spondyloarthritis: Evaluation of Different MRI Techniques and Two Scoring Methods. Journal of Rheumatology, 2014, 41, 473-480.	2.0	25
137	Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Annals of the Rheumatic Diseases, 2014, 73, 817-823.	0.9	236
138	Consistently Good Clinical Response in Patients with Early Axial Spondyloarthritis After 3 Years of Continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial. Journal of Rheumatology, 2014, 41, 2034-2040.	2.0	27
139	Response to H Zeidler's comments on the INFAST study. Annals of the Rheumatic Diseases, 2014, 73, e19-e19.	0.9	2
140	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. Arthritis and Rheumatology, 2014, 66, 2649-2656.	5.6	81
141	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2014, 73, 6-16.	0.9	397
142	Inflammation, new bone formation and treatment options in axial spondyloarthritis. Annals of the Rheumatic Diseases, 2014, 73, 1439-1441.	0.9	12
143	215. Sustained Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Two Years of Adalimumab Treatment. Rheumatology, 2014, 53, i140-i140.	1.9	1

144 Overview of Axial Spondyloarthritis. , 2014, , 5-16.

#	Article	IF	CITATIONS
145	Diagnosis of Axial Spondyloarthritis. , 2014, , 31-45.		3
146	Clinical Manifestations of Axial Spondyloarthritis. , 2014, , 17-29.		0
147	Management of Axial Spondyloarthritis. , 2014, , 59-96.		2
148	Treatment Challenges in Axial Spondylarthritis and Future Directions. Current Rheumatology Reports, 2013, 15, 356.	4.7	5
149	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 382, 1705-1713.	13.7	518
150	Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC). Annals of the Rheumatic Diseases, 2013, 72, 1430-1432.	0.9	67
151	Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1â€year of treatment with etanercept: results from the ESTHER trial. Annals of the Rheumatic Diseases, 2013, 72, 823-825.	0.9	100
152	Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?. Arthritis and Rheumatism, 2013, 65, 12-20.	6.7	96
153	Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Annals of the Rheumatic Diseases, 2013, 72, 815-822.	0.9	449
154	Magnetic Resonance Imaging Compared to Conventional Radiographs for Detection of Chronic Structural Changes in Sacroiliac Joints in Axial Spondyloarthritis. Journal of Rheumatology, 2013, 40, 1557-1565.	2.0	55
155	Review: Nonradiographic axial spondyloarthritis: New definition of an old disease?. Arthritis and Rheumatism, 2013, 65, 543-551.	6.7	153
156	In Situ Analysis of Interleukin–23– and Interleukinâ€12–Positive Cells in the Spine of Patients With Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 1522-1529.	6.7	121
157	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Annals of the Rheumatic Diseases, 2013, 72, 1646-1653.	0.9	127
158	Vertebral Erosions Associated with Spinal Inflammation in Patients with Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes After 2 Years of Tumor Necrosis Factor Inhibitor Therapy. Journal of Rheumatology, 2013, 40, 1891-1896.	2.0	17
159	Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Annals of the Rheumatic Diseases, 2013, 72, 967-973.	0.9	109
160	Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Annals of the Rheumatic Diseases, 2013, 72, 1621-1627.	0.9	93
161	One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Annals of the Rheumatic Diseases, 2013, 72, 305-306.	0.9	47
162	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: TableÂ1. Annals of the Rheumatic Diseases, 2013, 72, ii2-ii34.	0.9	114

#	Article	IF	CITATIONS
163	A4.11â€Baseline Elevated Serum Levels of Calprotectin as Independent Marker for Radiographic Spinal Progression in Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2013, 72, A28.1-A28.	0.9	0
164	Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 700-706.	0.9	80
165	Referral strategies for early diagnosis of axial spondyloarthritis. Nature Reviews Rheumatology, 2012, 8, 262-268.	8.0	111
166	Radiographic progression in ankylosing spondylitis/axial spondyloarthritis. Current Opinion in Rheumatology, 2012, 24, 363-369.	4.3	48
167	How to screen for axial spondyloarthritis in primary care?. Current Opinion in Rheumatology, 2012, 24, 359-362.	4.3	15
168	The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic. Annals of the Rheumatic Diseases, 2012, 71, 1998-2001.	0.9	60
169	Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Annals of the Rheumatic Diseases, 2012, 71, 1212-1215.	0.9	82
170	Preface. Rheumatic Disease Clinics of North America, 2012, 38, xvii-xxi.	1.9	0
171	How Important is Early Therapy in Axial Spondyloarthritis?. Rheumatic Disease Clinics of North America, 2012, 38, 635-642.	1.9	17
172	Differential synovial Th1 cell reactivity towards <i>Escherichia coli</i> antigens in patients with ankylosing spondylitis and rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, 1573-1576.	0.9	19
173	How to define remission in ankylosing spondylitis?. Annals of the Rheumatic Diseases, 2012, 71, i93-i95.	0.9	29
174	High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 572-574.	0.9	201
175	Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Annals of the Rheumatic Diseases, 2012, 71, 1616-1622.	0.9	286
176	Developments in therapies for spondyloarthritis. Nature Reviews Rheumatology, 2012, 8, 280-287.	8.0	47
177	Classification, Diagnosis, and Referral of Patients with Axial Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 477-485.	1.9	21
178	Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study. Rheumatology International, 2012, 32, 2801-2808.	3.0	29
179	Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Annals of the Rheumatic Diseases, 2012, 71, 1278-1288.	0.9	218
180	Baseline radiographic damage, elevated acuteâ€phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis and Rheumatism, 2012, 64, 1388-1398.	6.7	384

#	Article	IF	CITATIONS
181	New insights into therapy—TNF blockade and beyond. Nature Reviews Rheumatology, 2011, 7, 78-80.	8.0	6
182	Evaluation of 2 Screening Strategies for Early Identification of Patients with Axial Spondyloarthritis in Primary Care. Journal of Rheumatology, 2011, 38, 2452-2460.	2.0	117
183	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 905-908.	0.9	365
184	Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Research and Therapy, 2011, 13, R95.	3.5	267
185	Impaired Peripheral Th1 CD4+ T Cell Response to Escherichia coli Proteins in Patients with Crohn's Disease and Ankylosing Spondylitis. Journal of Clinical Immunology, 2011, 31, 998-1009.	3.8	20
186	Predicting the outcome of ankylosing spondylitis therapy. Annals of the Rheumatic Diseases, 2011, 70, 973-981.	0.9	158
187	Synovial and Peripheral Blood CD4+FoxP3+ T Cells in Spondyloarthritis. Journal of Rheumatology, 2011, 38, 2445-2451.	2.0	44
188	Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 yearsearly clinical response predicts long-term outcome. Rheumatology, 2011, 50, 1690-1699.	1.9	105
189	Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1369-1374.	0.9	293
190	Relation of HLA-B27, Tumor Necrosis Factor-α Promoter Gene Polymorphisms, and T Cell Cytokine Production in Ankylosing Spondylitis — A Comprehensive Genotype-Phenotype Analysis from an Observational Cohort. Journal of Rheumatology, 2011, 38, 2436-2441.	2.0	18
191	ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 249-251.	0.9	208
192	Management of ankylosing spondylitis. , 2011, , 1157-1177.e3.		2
193	Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?. Current Opinion in Rheumatology, 2010, 22, 388-392.	4.3	14
194	Investigation of involved tissue in axial spondyloarthritis – what have we learnt from immunohistochemical studies?. Best Practice and Research in Clinical Rheumatology, 2010, 24, 715-719.	3.3	8
195	Current Controversies in Spondyloarthritis: SPARTAN. Journal of Rheumatology, 2010, 37, 2617-2623.	2.0	11
196	Immunohistochemical Analysis of Osteoblasts in Zygapophyseal Joints of Patients with Ankylosing Spondylitis Reveal Repair Mechanisms Similar to Osteoarthritis. Journal of Rheumatology, 2010, 37, 823-828.	2.0	39
197	The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort. Arthritis and Rheumatism, 2009, 60, 717-727.	6.7	605
198	HLA–B27–restricted antigen presentation by human chondrocytes to CD8+ T cells: Potential contribution to local immunopathologic processes in ankylosing spondylitis. Arthritis and Rheumatism, 2009, 60, 1635-1646.	6.7	21

#	Article	IF	CITATIONS
199	Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis and Rheumatism, 2009, 60, 3257-3262.	6.7	282
200	Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Research and Therapy, 2009, 11, R124.	3.5	68
201	Developments in the scientific and clinical understanding of the spondyloarthritides. Arthritis Research and Therapy, 2009, 11, 208.	3.5	41
202	Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis. Journal of Rheumatology, 2009, 36, 801-808.	2.0	189
203	Can structural damage be prevented in ankylosing spondylitis?. Current Opinion in Rheumatology, 2009, 21, 335-339.	4.3	20
204	Socioeconomic aspects of ankylosing spondylitis. , 2009, , 73-73.		0
205	Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics. Current Rheumatology Reports, 2008, 10, 356-363.	4.7	25
206	Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes. Arthritis and Rheumatism, 2008, 58, 649-656.	6.7	206
207	Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelveâ€week randomized, doubleâ€blind, placeboâ€controlled trial followed by an open″abel extension up to week fiftyâ€two. Arthritis and Rheumatism, 2008, 58, 1981-1991.	6.7	293
208	Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, doubleâ€blind, placeboâ€controlled, phase III trial. Arthritis and Rheumatism, 2008, 58, 3402-3412.	6.7	512
209	Efficacy and safety of infliximab in patients with ankylosing spondylitis over a twoâ€year period. Arthritis and Rheumatism, 2008, 59, 1270-1278.	6.7	98
210	Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Research and Therapy, 2008, 10, R125.	3.5	53
211	The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Research and Therapy, 2008, 10, R104.	3.5	211
212	The safety of celecoxib in ankylosing spondylitis treatment. Expert Opinion on Drug Safety, 2008, 7, 401-409.	2.4	7
213	Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis. Nature Clinical Practice Rheumatology, 2008, 4, 578-579.	3.2	7
214	Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?. Nature Clinical Practice Rheumatology, 2008, 4, 398-399.	3.2	1
215	Adalimumab for the treatment of ankylosing spondylitis. Expert Opinion on Pharmacotherapy, 2007, 8, 831-838.	1.8	18
216	Ankylosing spondylitis. Lancet, The, 2007, 369, 1379-1390.	13.7	1,558

#	Article	IF	CITATIONS
217	Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Annals of the Rheumatic Diseases, 2007, 66, 1479-1484.	0.9	153
218	Homologous high-throughput expression and purification of highly conserved E coli proteins. Microbial Cell Factories, 2007, 6, 18.	4.0	12
219	Diagnosing early ankylosing spondylitis. Current Rheumatology Reports, 2007, 9, 367-374.	4.7	21
220	Pathogenesis of Reactive Arthritis. , 2007, , 181-187.		0
221	Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. Journal of Rheumatology, 2007, 34, 510-5.	2.0	47
222	Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Research and Therapy, 2006, 8, R143.	3.5	153
223	Concepts and epidemiology of spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2006, 20, 401-417.	3.3	196
224	Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two–week open-label trial. Arthritis and Rheumatism, 2006, 54, 678-681.	6.7	150
225	Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis and Rheumatism, 2006, 54, 569-578.	6.7	472
226	Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone–cartilage interface and subchondral bone marrow. Arthritis and Rheumatism, 2006, 54, 1805-1813.	6.7	139
227	Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, doubleâ€blind, placeboâ€controlled trial. Arthritis and Rheumatism, 2006, 54, 2136-2146.	6.7	768
228	Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2006, 54, 2845-2851.	6.7	172
229	Identification of immunodominant CD4+ T cell epitopes in patients withYersinia-induced reactive arthritis by cytometric cytokine secretion assay. Arthritis and Rheumatism, 2006, 54, 3583-3590.	6.7	8
230	Early diagnosis of spondyloarthritis. Nature Clinical Practice Rheumatology, 2006, 2, 536-545.	3.2	26
231	Reactive Spondyloarthritis: Epidemiology, Clinical Features, and Treatment. , 2006, , 53-64.		10
232	Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. Journal of Rheumatology, 2006, 33, 86-90.	2.0	71
233	Diverse effects of infliximab and etanercept on T lymphocytes. Seminars in Arthritis and Rheumatism, 2005, 34, 23-27.	3.4	44
234	Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placeboâ€controlled trial (ASSERT). Arthritis and Rheumatism, 2005, 52, 582-591.	6.7	773

#	Article	IF	CITATIONS
235	HLA–B27–restricted CD8+ T cell response to cartilageâ€derived self peptides in ankylosing spondylitis. Arthritis and Rheumatism, 2005, 52, 892-901.	6.7	108
236	The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria?. Arthritis and Rheumatism, 2005, 52, 1000-1008.	6.7	448
237	Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Research, 2005, 7, R439.	2.0	233
238	Identification of Novel Human Aggrecan T Cell Epitopes in HLA-B27 Transgenic Mice Associated with Spondyloarthropathy. Journal of Immunology, 2004, 173, 4859-4866.	0.8	39
239	Fluoroscopy-guided application of corticosteroids for local control of manubriosternal joint pain in patients with spondyloarthropathies. Clinical Rheumatology, 2004, 23, 481-484.	2.2	11
240	Disease mechanisms in reactive arthritis. Current Rheumatology Reports, 2004, 6, 110-116.	4.7	23
241	Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. Journal of Rheumatology, 2004, 31, 531-8.	2.0	65
242	Identification of HLA-B27–restricted peptides in reactive arthritis and other spondyloarthropathies. Rheumatic Disease Clinics of North America, 2003, 29, 595-611.	1.9	19
243	Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opinion on Biological Therapy, 2003, 3, 141-168.	3.1	2
244	Anti-TNF agents for the treatment of spondyloarthropathies. Expert Opinion on Emerging Drugs, 2002, 7, 235-246.	2.4	13
245	Diagnosing reactive arthritis: Role of clinical setting in the value of serologic and microbiologic assays. Arthritis and Rheumatism, 2002, 46, 319-327.	6.7	120
246	Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. Journal of Rheumatology, 2002, 29, 118-22.	2.0	103
247	Pathogenesis of reactive arthritis. Current Rheumatology Reports, 2001, 3, 412-418.	4.7	41
248	Identification of HLA-B27-Restricted Peptides from the <i>Chlamydia trachomatis</i> Proteome with Possible Relevance to HLA-B27-Associated Diseases. Journal of Immunology, 2001, 167, 4738-4746.	0.8	125
249	Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab. Arthritis and Rheumatism, 2000, 43, 1346-1352.	6.7	506
250	Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis and Rheumatism, 2000, 43, 2834-2842.	6.7	75
251	Multispecific CD4+ T Cell Response to a Single 12-mer Epitope of the Immunodominant Heat-Shock Protein 60 of <i>Yersinia enterocolitica </i> in <i>Yersinia </i> -Triggered Reactive Arthritis: Overlap with the B27-Restricted CD8 Epitope, Functional Properties, and Epitope Presentation by Multiple DR Alleles. Journal of Immunology, 2000, 164, 1529-1537.	0.8	55
252	No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis and Rheumatism, 1999, 42, 1386-1396.	6.7	149

#	Article	IF	CITATIONS
253	Low secretion of tumor necrosis factor ?, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis and Rheumatism, 1999, 42, 2039-2044.	6.7	133
254	Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis and Rheumatism, 1998, 41, 58-67.	6.7	854
255	Characterization of the synovial T cell response to various recombinantYersinia antigens inYersinia enterocolitica-triggered reactive arthritis: Heat-shock protein 60 drives a major immune response. Arthritis and Rheumatism, 1998, 41, 315-326.	6.7	89
256	Crucial role of interleukinâ€10/interleukinâ€12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis and Rheumatism, 1997, 40, 1788-1797.	6.7	158
257	Pathogenesis of spondylarthropathies. Arthritis and Rheumatism, 1995, 38, 1547-1554.	6.7	175
258	The Evolutionarily Conserved Ribosomal Protein L23 and the Cationic Urease β-Subunit of Yersinia enterocolitica O:3 Belong to the Immunodominant Antigens in Yersinia-Triggered Reactive Arthritis: Implications for Autoimmunity. Molecular Medicine, 1994, 1, 44-55.	4.4	35
259	Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis and Rheumatism, 1994, 37, 1039-1045.	6.7	320